Kyverna Therapeutics, Inc. SEC filings KYTX
Kyverna Therapeutics, Inc. has 187 filings in SEC EDGAR's recent list, going back to Oct 5, 2023. Its latest annual report, Form ARS, was filed on Apr 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 24, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 2, 2026 | — |
| CORRESP | Letter to the SEC | Mar 31, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2026 | — |
| EFFECT | Filing | Apr 15, 2025 | — |
| CORRESP | Letter to the SEC | Apr 11, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2024 | — |
| SEC STAFF LETTER | Filing | Feb 13, 2024 | — |
| CERT | Filing | Feb 8, 2024 | — |
| EFFECT | Filing | Feb 7, 2024 | — |
| CORRESP | Letter to the SEC | Feb 5, 2024 | — |
| CORRESP | Letter to the SEC | Feb 5, 2024 | — |
| 8-A12B | Filing | Feb 5, 2024 | — |
| CORRESP | Letter to the SEC | Jan 25, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 10, 2024 | — |
| DRS/A | Filing | Jan 8, 2024 | — |
| DRSLTR | Filing | Jan 5, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 28, 2023 | — |
| SEC STAFF LETTER | Filing | Dec 15, 2023 | — |
| DRSLTR | Filing | Dec 13, 2023 | — |
| DRS/A | Filing | Dec 13, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2023 | — |
| DRSLTR | Filing | Nov 9, 2023 | — |
| DRS/A | Filing | Nov 9, 2023 | — |
| D | Filing | Nov 7, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2023 | — |
| DRS | Filing | Oct 5, 2023 | — |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KYTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1994702
- Former names
- Kyverna Therapeutics, Inc. (until Oct 19, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.